AM - Antero Midstream Corporation
B. Riley Wealth Advisors Inc. purchased a new position in shares of Antero Midstream Corporation (NYSE: AM) during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 27,599 shares of the pipeline company's stock, valued at approximately $556,000. A number of other
On October 16, 2026, Antero Midstream Corp (AM) shares rose by 3.6%, currently priced at $20.64. Over the past year, the stock has fluctuated between a low of $
DENVER, Oct. 14, 2026 /PRNewswire/ -- Antero Midstream Corporation (NYSE: AM) ("Antero Midstream" or the "Company") today announced that the Board of Directors of Antero Midstream declared a cash dividend of $0.225 per share for the third quarter of 2026. The Company also repurchased approximately 1.3 million shares during the third quarter.
Realty Income and similar income stocks now struggle to deliver inflation-beating returns, with dividend growth lagging recent price increases. In today's higher-rate, post-2020 inflationary environment, traditional income favorites offer little premium over bonds and limited inflation protection. My income safety test reveals that many beloved REITs and dividend stocks fail to preserve purchasing power, making them riskier for retirees.
Bank of Nova Scotia purchased a new stake in Antero Midstream Corporation (NYSE: AM) in the undefined quarter, according to its most recent filing with the SEC. The institutional investor purchased 165,422 shares of the pipeline company's stock, valued at approximately $3,763,000. Several other hedge funds also recently added to or reduced their
Great Lakes Advisors LLC bought a new stake in shares of Antero Midstream Corporation (NYSE: AM) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 26,938 shares of the pipeline company's stock, valued at approximately $613,000. A number of other hedge funds
Abacus FCF Advisors LLC bought a new position in Antero Midstream Corporation (NYSE: AM) during the second quarter, according to the company in its most recent filing with the SEC. The firm bought 474,204 shares of the pipeline company's stock, valued at approximately $10,788,000. Antero Midstream accounts for approximately 2.0% of Abacus FCF
Amundi cut its stake in Antero Midstream Corporation (NYSE: AM) by 31.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 550,311 shares of the pipeline company's stock after selling 251,909 shares during the quarter. Amundi owned approximately 0.12% of Antero
/PRNewswire/ -- Beginning in the 2026-2027 athletic season, Antero will be the Official Jersey Patch Sponsor of West Virginia University (WVU) Department of
Income investors do not need to write big checks to build a meaningful dividend stream.
Arrowstreet Capital Limited Partnership acquired a new stake in shares of Antero Midstream Corporation (NYSE: AM) during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 194,808 shares of the pipeline company's stock, valued at approximately $4,442,000. Several other institutional investors have also
California State Teachers Retirement System raised its position in Antero Midstream Corporation (NYSE: AM) by 26.3% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 426,913 shares of the pipeline company's stock after purchasing an additional 88,900 shares during the period. California State Teachers Retirement
While the top- and bottom-line numbers for Antero Midstream (AM) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
DENVER, July 29, 2026 /PRNewswire/ -- Antero Midstream Corporation (NYSE: AM) ("Antero Midstream" or the "Company") today announced its second quarter 2026 financial and operating results. The relevant consolidated financial statements are included in Antero Midstream's Quarterly Report on Form 10-Q for the three months ended June 30, 2026.
Cetera Investment Advisers grew its position in shares of Antero Midstream Corporation (NYSE: AM) by 9.9% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 867,200 shares of the pipeline company's stock after buying an additional 77,936 shares during the quarter.
Bessemer Group Inc. reduced its stake in Antero Midstream Corporation (NYSE: AM) by 91.2% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 16,112 shares of the pipeline company's stock after selling 166,796 shares during the period. Bessemer Group Inc.'s
DENVER, July 15, 2026 /PRNewswire/ -- Antero Midstream Corporation (NYSE: AM) ("Antero Midstream" or the "Company") today announced that the Board of Directors of Antero Midstream declared a cash dividend of $0.225 per share for the second quarter of 2026. The Company also repurchased approximately 0.4 million shares during the second quarter.
Carillon Eagle Mid Cap Growth Fund stocks delivered solid results in the second quarter. Top securities in the quarter were Datadog, Marvell, Vertiv, Teradyne and Macom Technology Solutions. Top securities in the quarter were Datadog, Marvell, Vertiv, Teradyne and Macom Technology Solutions.
Results from Study AM-001 mark a pivotal advance through the transition to a once daily lower 400mg dose of AM enabling: Production of GMP clinical batch for Galmed's upcoming clinical trials Solidification and prolongation of Aramchol's IP protection Potential reduction in drug CoGs by ~50% Improvement in patients' convenience and compliance upon potential commercialization RAMAT-GAN, Israel, May 14, 2026 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver disease and GI oncological therapeutics, announced today major milestone results from a Phase 1 PK study in healthy subjects (Study AM-001).
The energy sector is the top performer this year, but investors shouldn't forget the group's attractive dividend profile.